This chapter examines the financial gains made by vaccine manufacturers like Pfizer and Moderna amidst the pandemic, highlighting government involvement and emerging conflicts of interest. It questions the competitive landscape of public health decisions, considering the exclusion of alternative medications and the implications of emergency use authorization. The discussion reveals concerns over the motivations behind labeling mRNA technology as a vaccine and the potential consequences for public perception and health protocols.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode